Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study

Abstract

Kun Zhang,1,2 Xiya Ma,2 Hongjun Gao,2 Hong Wang,2 Haifeng Qin,2 Shaoxing Yang,2 Xiaoqing Liu2 1Academy of Military Medical Science, Beijing 100089, People’s Republic of China; 2Department of Lung Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, People’s Republic of ChinaCorrespondence: Xiaoqing LiuDepartment of Lung Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No. 8 East Street, Fengtai District, Beijing 100071, People’s Republic of ChinaTel + 8610-66947963Fax + 8610-51128605Email [email protected]: The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase inhibitor, administered as third-line or further treatment prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). This retrospective study investigated the efficacy and safety of anlotinib in real-world settings.Patients and Methods: Medical records of patients with advanced NSCLC receiving anlotinib as third-line or further treatment were collected, and survival curves were derived using the Kaplan–Meier method. Univariate analysis was performed by log-rank testing. Cox regression analysis was used to evaluate the significance of factors obtained from the univariate analysis.Results: Fifty-two patients with advanced NSCLC were included. The objective response rate was 16%, and the disease control rate was 80%. The median PFS was 4.5 months (95% confidence interval [CI]: 3.6– 5.4), and the median OS was 9 months (95% CI: 6.5– 11.5). Univariate analysis revealed that the group of patients with longer PFS and OS included Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1, ≤ 2 distant metastases, no liver metastases, ≤ 3 previous treatment lines, and ≤ 2 previous chemotherapy lines. Cox regression analysis demonstrated that only patients with ECOG PS ≤ 1 or no liver metastases had longer PFS and OS. Grade 3 treatment-related adverse events were reported in 14% of the patients, but no life-threatening adverse events were reported.Conclusion: Anlotinib was well tolerated and effective in patients with advanced NSCLC in real-world conditions. Patients with ECOG PS ≤ 1 or no liver metastases have longer PFS and OS.Keywords: anlotinib, non-small cell lung cancer, antiangiogenesis, third-line or further treatment, real-world study

Keywords

• anlotinib
• non-small cell lung cancer
• antiangiogenesis
• third-line or further treatment
• real-world study